Immunoadjuvant activity of interferon-γ-liposomes co-administered with influenza vaccines

被引:20
作者
van Slooten, ML
Hayon, I
Babai, I
Zakay-Rones, Z
Wagner, E
Storm, G
Kedar, E
机构
[1] Univ Utrecht, Fac Pharm, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Immunol, IL-91010 Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Virol, IL-91010 Jerusalem, Israel
[4] Boehringer Ingelheim Austrial GmbH, Vienna, Austria
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2001年 / 1531卷 / 1-2期
基金
以色列科学基金会;
关键词
liposome; drug delivery system; influenza vaccine; interferon-gamma;
D O I
10.1016/S1388-1981(01)00092-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In an attempt to potentiate the relatively low immunogenicity of the currently used influenza vaccines, especially in highrisk groups, monovalent and divalent subunit vaccine preparations were co-administered with free or liposome-associated murine interferon gamma (mIFN gamma) as an adjuvant. Recombinant murine IFN gamma was entrapped (50-70% efficiency) in two types of large multilamellar vesicles: mIFN gamma -LIP A-'conventional' liposomes, and mIFN gamma -LIP B- 'surface-depleted' liposomes, in which 60 and 8% of the associated cytokine was located at the external liposome membrane, respectively. Subunit preparations containing the viral surface proteins hemagglutinin and neuraminidase (HN) were injected once, i.p. (0.5 mug each), into BALB/c mice, alone and combined with free or liposomal mIFN gamma (mIFN gamma -LIP, 0.5 or 3.0 mug). Sera were tested 3-16 weeks post-vaccination by hemagglutination inhibition (HI), and by ELISA for IgGl and IgG2a antibodies (Abs). In addition, protective immunity against intranasal viral infection was assayed at 11 and 17 weeks post-vaccination. The results showed that: (a) Vaccination with HN alone produces very low HI and IgG titers and does not afford any protection. (b) Although co-administration with free mIFN gamma (particularly using 3.0 mug) markedly enhances HI titer as well as the IgGl and IgG2a levels, protection is negligible (0-33%). (c) In most cases, mIFN gamma -LIP is significantly more potent than free mIFN gamma (2-40-fold increase in Ab titer), and the low dose (0.5 mug) is generally more efficient than the high dose. Up to 83% of the mice co-vaccinated with mIFN gamma -LIP were protected against viral challenge. (d) Both the IgG2a level and the HI titer appear to be crucial for protection. (e) Although the two liposomal preparations differ in their cytokine release profile in vivo and in their bioactivity in vitro, their adjuvant activity is comparable. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:99 / 110
页数:12
相关论文
共 52 条
[1]  
ADA GL, 1986, CURR TOP MICROBIOL, V128, P1
[2]  
Alving C.R, 1997, NEW GENERATION VACCI, P207
[3]  
ANDERSON KP, 1988, J IMMUNOL, V140, P3599
[4]   A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice [J].
Babai, I ;
Samira, S ;
Barenholz, Y ;
Zakay-Rones, Z ;
Kedar, E .
VACCINE, 1999, 17 (9-10) :1223-1238
[5]   A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice [J].
Babai, I ;
Samira, S ;
Barenholz, Y ;
Zakay-Rones, Z ;
Kedar, E .
VACCINE, 1999, 17 (9-10) :1239-1250
[6]   IMMUNOGLOBULIN-G SUBCLASS ANTIBODY-RESPONSES OF MICE TO INFLUENZA-VIRUS ANTIGENS GIVEN IN DIFFERENT FORMS [J].
BALKOVIC, ES ;
FLORACK, JA ;
SIX, HR .
ANTIVIRAL RESEARCH, 1987, 8 (03) :151-160
[7]   Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants [J].
Benne, CA ;
Harmsen, M ;
vanderGraaff, W ;
Verheul, AFM ;
Snippe, H ;
Kraaijeveld, CA .
VACCINE, 1997, 15 (09) :1039-1044
[8]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[9]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
[10]   ENHANCEMENT OF THE PROTECTIVE EFFECT OF INACTIVATED INFLUENZA-VIRUS VACCINE BY CYTOKINES [J].
CAO, M ;
SASAKI, O ;
YAMADA, A ;
IMANISHI, J .
VACCINE, 1992, 10 (04) :238-242